PLOD3 and Marinesco-Sjogren syndrome: CRCs with higher PLOD3 expression showed a lower TMB, a higher TIDE score, and patients with MSS tended to have higher PLOD3 expression, suggesting that these patients could present with immunotherapy resistance.